Further population-based studies may quantify incidence rates, characterize dose-dependent relationships, and investigate mechanistic pathways to optimize risk stratification and therapeutic decision-making
The FDA has issued warning letters to entities marketing peptides for human use and has worked with the DEA in some instances to characterize improperly labeled peptides as misbranded or unapproved drugs
FDA is working with Novo Nordisk to identify, investigate and remove further suspected counterfeit Ozempic injectable products found in the U.S
Anti-inflammatory properties of exenatide in human pancreatic islets
Our goal is zero complaints
Sources reviewed include: the official FeelGood website at feelgoodmeds.com, the brand's published Cancellation and Refund Policy, Terms of Use (last updated July 2025), the OpenLoop Healthcare Partners, PC telehealth consent form published at openloophealth.com, LegitScript verification data, and category-level published research on GLP-1 receptor agonists from NIDDK, NIH, and peer-reviewed clinical literature